Fig. 6
ADAM17 regulated the AMPK-TFEB pathway in vivo and in vitro. a Representative Western blot images of protein expression of phosphorylated AMPK, AMPK, and TFEB in the myocardium of four groups of mice. b, c Quantitative analysis of phosphorylated AMPK/AMPK and TFEB expression in the myocardium of four groups mice, n = 6. Data were expressed as mean ± SEM. ***P < 0.001 vs. the A17fl/fl control group; ###P < 0.001 vs. the A17fl/fl DM group. d–f Representative Western blot images and quantitative analysis of phosphorylated AMPK, AMPK, and TFEB protein expression in eight groups of differentiated H9c2 cells treated with vehicle, GP, GP + NC-siRNA, and GP + ADAM17-siRNA, with and without additional chloroquine (CQ) treatment, respectively. Mean values were obtained from five independent experiments. g–i Representative Western blot images and quantitative analysis of phosphorylated AMPK, AMPK, and TFEB protein expression in eight groups of NRCMs treated as above. j Representative immunofluorescence staining of TFEB (red) in eight groups of differentiated H9c2 cells (scale bar: 20 μm) treated as above. k Representative immunofluorescence staining of TFEB (red) in eight groups of NRCMs treated as above (scale bar: 20 μm). l Quantification of TFEB-positive nucleus ratio in differentiated H9c2 cells. Mean values were derived from five independent experiments. m Quantification of TFEB-positive nucleus ratio in NRCMs. Six independent experiments were performed to derive the mean values. Data were expressed as mean ± SEM. **P < 0.01, ***P < 0.001 vs. the vehicle group; ##P < 0.01, ###P < 0.001 vs. the GP + NC-siRNA group. n Representative immunofluorescence staining of TFEB and cTnT in four groups of mice (scale bar: 20 μm). o Quantification of TFEB-positive nucleus ratio in cardiomyocytes of four groups of mice, n = 6. Data were presented as mean ± SEM. **P < 0.01 vs. the A17fl/fl control group; ##P < 0.01 vs. the A17fl/fl DM group
